Zotatifin

Generic Name
Zotatifin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C28H29N3O5
CAS Number
2098191-53-6
Unique Ingredient Identifier
2EWN8Z05CN
Background

Zotatifin is under investigation in clinical trial NCT04092673 (Study of Eft226 in Subjects With Selected Advanced Solid Tumor Malignancies).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer

First Posted Date
2021-11-01
Last Posted Date
2024-07-11
Lead Sponsor
Stanford University
Target Recruit Count
19
Registration Number
NCT05101564
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Stanford University, Stanford, California, United States

Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

Phase 1
Completed
Conditions
Corona Virus Infection
Interventions
Drug: Placebo
Drug: Zotatifin
First Posted Date
2020-11-17
Last Posted Date
2023-10-05
Lead Sponsor
Effector Therapeutics
Target Recruit Count
36
Registration Number
NCT04632381
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cullman Clinical Trials, Cullman, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Pinnacle Research Group, Anniston, Alabama, United States

๐Ÿ‡บ๐Ÿ‡ธ

Tampa General Hospital, Tampa, Florida, United States

and more 1 locations

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer

First Posted Date
2018-09-18
Last Posted Date
2024-11-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
130
Registration Number
NCT03675893
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dana Farber Cancer Institute, Boston, Massachusetts, United States

ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy